Safety, efficacy, and patient acceptability of single-dose fosaprepitant regimen for the prevention of chemotherapy-induced nausea and vomiting

Por Celio, Luigi, Ricchini, Francesca, De Braud, Filippo
Publicado em 2013

Continuing Single-Agent Bevacizumab as Maintenance Therapy After Induction XELOX (or FOLFOX) Plus Bevacizumab in First-Line Treatment of Metastatic Colorectal Cancer

Por Díaz-Rubio, Eduardo, Pietrantonio, Filippo, de Braud, Filippo
Publicado em 2012

Lymphoma Immunotherapy: Current Status

Por Zappasodi, Roberta, de Braud, Filippo, Di Nicola, Massimo
Publicado no Front Immunol (2015)

First line treatment of metastatic renal cell carcinoma: Two standards with different toxicity profile

Por Iacovelli, Roberto, Verzoni, Elena, De Braud, Filippo, Procopio, Giuseppe
Publicado em 2014

Study design and clinical evidence in mRCC: Can we save axitinib as a first-line therapy?

Por Iacovelli, Roberto, Verzoni, Elena, De Braud, Filippo Maria, Procopio, Giuseppe
Publicado em 2014

Should clinicians always administer dexamethasone beyond 24 h after chemotherapy to control delayed nausea and vomiting caused by moderately emetogenic regimens? Insight from the r...

Por Celio, Luigi, Bonizzoni, Erminio, De Braud, Filippo, Agustoni, Francesco, Aapro, Matti
Publicado no Support Care Cancer (2015)

Experience with sorafenib in the treatment of advanced renal cell carcinoma

Por Procopio, Giuseppe, Verzoni, Elena, Testa, Isabella, Nicolai, Nicola, Salvioni, Roberto, DeBraud, Filippo
Publicado em 2012

Sites of disease as predictors of outcome in metastatic renal cell carcinoma patients treated with first-line sunitinib or sorafenib

Por Grassi, Paolo, Verzoni, Elena, Porcu, Luca, Iacovelli, Roberto, de Braud, Filippo, Procopio, Giuseppe
Publicado no Ther Adv Urol (2015)

Cabozantinib in the treatment of advanced renal cell carcinoma: design, development, and potential place in the therapy

Por Grassi, Paolo, Verzoni, Elena, Ratta, Raffaele, Mennitto, Alessia, de Braud, Filippo, Procopio, Giuseppe
Publicado no Drug Des Devel Ther (2016)

Targeting cancer metabolism: dietary and pharmacological interventions

Por Vernieri, Claudio, Casola, Stefano, Foiani, Marco, Pietrantonio, Filippo, de Braud, Filippo, Longo, Valter
Publicado no Cancer Discov (2016)

HER2-Positive Neuroendocrine Breast Cancer: Case Report and Review of Literature

Por Gevorgyan, Arpine, Bregni, Giacomo, Galli, Giulia, Zanardi, Elisa, de Braud, Filippo, Di Cosimo, Serena
Publicado no Breast Care (Basel) (2016)

Biological insights into BRAF(V600) mutations in melanoma patient: Not mere therapeutic targets

Por Improta, Giuseppina, Pelosi, Giuseppe, Tamborini, Elena, Donia, Marco, Santinami, Mario, de Braud, Filippo, Fraggetta, Filippo
Publicado em 2013

Safety of long-term exposure to abiraterone acetate in patients with castration-resistant prostate cancer and concomitant cardiovascular risk factors

Por Verzoni, Elena, Grassi, Paolo, Ratta, Raffaele, Niger, Monica, De Braud, Filippo, Valdagni, Riccardo, Procopio, Giuseppe
Publicado no Ther Adv Med Oncol (2016)

Incidence and relative risk of grade 3 and 4 diarrhoea in patients treated with capecitabine or 5- fluorouracil: a meta-analysis of published trials

Por Iacovelli, Roberto, Pietrantonio, Filippo, Palazzo, Antonella, Maggi, Claudia, Ricchini, Francesca, de Braud, Filippo, Di Bartolomeo, Maria
Publicado no Br J Clin Pharmacol (2014)

Bevacizumab treatment in the elderly patient with metastatic colorectal cancer

Por Di Bartolomeo, Maria, Maggi, Claudia, Ricchini, Francesca, Pietrantonio, Filippo, Iacovelli, Roberto, de Braud, Filippo, Inno, Alessandro
Publicado no Clin Interv Aging (2015)

In Reply

Por Baratti, Dario, Kusamura, Shigeki, Maggi, Claudia, de Braud, Filippo, Deraco, Marcello, Di Bartolomeo, Maria, Pietrantonio, Filippo
Publicado no Oncologist (2015)

Targeted treatments in advanced renal cell carcinoma: focus on axitinib

Por Verzoni, Elena, Grassi, Paolo, Testa, Isabella, Iacovelli, Roberto, Biondani, Pamela, Garanzini, Enrico, De Braud, Filippo, Procopio, Giuseppe
Publicado em 2014

Clinical experience with temsirolimus in the treatment of advanced renal cell carcinoma

Por Zanardi, Elisa, Verzoni, Elena, Grassi, Paolo, Necchi, Andrea, Giannatempo, Patrizia, Raggi, Daniele, De Braud, Filippo, Procopio, Giuseppe
Publicado no Ther Adv Urol (2015)

Bax Expression Is Predictive of Favorable Clinical Outcome in Chemonaive Advanced Gastric Cancer Patients Treated with Capecitabine, Oxaliplatin, and Irinotecan Regimen

Por Pietrantonio, Filippo, Biondani, Pamela, de Braud, Filippo, Pellegrinelli, Alessandro, Bianchini, Giampaolo, Perrone, Federica, Formisano, Barbara, Di Bartolomeo, Maria
Publicado em 2012

Succinate Dehydrogenase B Subunit Immunohistochemical Expression Predicts Aggressiveness in Well Differentiated Neuroendocrine Tumors of the Ileum

Por Milione, Massimo, Pusceddu, Sara, Gasparini, Patrizia, Melotti, Flavia, Maisonneuve, Patrick, Mazzaferro, Vincenzo, de Braud, Filippo G., Pelosi, Giuseppe
Publicado em 2012